(SKYE)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Skye Bioscience, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, semizlik, ortiqcha vazn va metabolik kasalliklarni davolash uchun G-protein bilan bog'langan retseptorlarni (GPCR) modulyatsiya qiluvchi molekulalarni ishlab chiqishga qaratilgan. Uning asosiy mahsulot nomzodi - nimacimab, periferik cheklangan salbiy allosterik modulyatsiya qiluvchi antiteladir, u metabolik regulyatsiyada ishtirok etadigan asosiy GPCR bo'lgan kannabinoid retseptor 1 ga qaratilgan. Kompaniya ilgari Emerald Bioscience, Inc. nomi bilan tanilgan va 2021-yil yanvar oyida Skye Bioscience, Inc. nomini o'zgartirgan. Skye Bioscience, Inc. Kaliforniyaning San-Diego shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Dr. Puneet S. Arora FACE, M.D., M.S. | Chief Medical Officer |
| Mr. Punit S. Dhillon B.A. | President, CEO, Principal Accounting Officer & Director |
| Mr. Tu Diep M.Sc. | Chief Operating Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-19 | 8-K | skye-20260317.htm |
| 2026-03-11 | S-8 | skye-03102026_sx8evergreen.htm |
| 2026-03-10 | 10-K | skye-20251231.htm |
| 2026-02-02 | 8-K | skye-20260202.htm |
| 2025-12-23 | 8-K | skye-20251218.htm |
| 2025-11-10 | 8-K | skye-20251110.htm |
| 2025-10-06 | 8-K | skye-20251006.htm |
| 2025-08-07 | 10-Q | skye-20250630.htm |
| 2025-06-11 | 8-K | skye-20250606.htm |
| 2025-05-08 | 10-Q | skye-20250331.htm |